Head to Head Analysis: IRIS International (IRIS) vs. NanoString Technologies (NSTG)
IRIS International (NASDAQ: IRIS) and NanoString Technologies (NASDAQ:NSTG) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.
This is a breakdown of recent recommendations and price targets for IRIS International and NanoString Technologies, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Insider and Institutional Ownership
68.9% of IRIS International shares are held by institutional investors. Comparatively, 92.7% of NanoString Technologies shares are held by institutional investors. 9.7% of IRIS International shares are held by company insiders. Comparatively, 24.4% of NanoString Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares IRIS International and NanoString Technologies’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|NanoString Technologies||$86.49 million||2.24||-$47.08 million||($2.07)||-3.70|
IRIS International has higher earnings, but lower revenue than NanoString Technologies. NanoString Technologies is trading at a lower price-to-earnings ratio than IRIS International, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
IRIS International has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Comparatively, NanoString Technologies has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500.
This table compares IRIS International and NanoString Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
NanoString Technologies beats IRIS International on 6 of the 10 factors compared between the two stocks.
IRIS International Company Profile
Mitcham Industries, Inc. is a provider of equipment to the geophysical, oceanographic and hydrographic industries. The Company operates through two segments. The Equipment Leasing segment is primarily engaged in the leasing of seismic equipment to companies in the oil and gas industry across the world. The Equipment Manufacturing and Sales segment is engaged in the design, production and sale of marine seismic equipment, and oceanographic and hydrographic equipment. Its leasing business includes Mitcham Canada ULC, Seismic Asia Pacific Pty Ltd., Mitcham Seismic Eurasia LLC, Mitcham Europe Ltd. and Mitcham Marine Leasing Pte. Ltd. The Equipment Manufacturing and Sales Segment includes its Seamap International Holdings Pte, Ltd. (Seamap) business and Klein Marine Systems, Inc. (Klein). Seamap designs, manufactures and sells a range of products for the seismic, hydrographic and offshore industries. Klein develops and manufactures high performance side scan sonar systems.
NanoString Technologies Company Profile
NanoString Technologies, Inc. develops, manufactures and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company is engaged in the development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. The Company’s nCounter Analysis System is an automated, multi-application, digital detection and counting system, which directly profiles hundreds of molecules simultaneously using a barcoding technology. The Company markets systems and related consumables to researchers in academic, government and biopharmaceutical laboratories for use in understanding fundamental biology and the molecular basis of diseases, such as cancer, and to clinical laboratories and medical centers for diagnostic use.
Receive News & Ratings for IRIS International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIS International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.